Patients Are at the Forefront of Everything We Do

With a vision of creating a healthier tomorrow, we are steadfast in our approach to translating novel biologic insights into targeted therapies for patients who have few to no treatment options. 

We are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs.

Our Clinical Trials

A 12-week, randomized, double-blind, placebo-controlled, Phase 3 study to assess the safety and efficacy of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) in pediatric patients 12 to less than 18 years old. ID NCT05643534
Status: Recruiting

This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects. ID NCT06203444
Status: Recruiting

Partners and Advocacy Collaborations